AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 302 min read$ANIP

CAREY STEPHEN P. sold $240K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 2,850 shares of ANI PHARMACEUTICALS INC (ANIP) at $84.12 ($0.24M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Jun 30, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 30, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIP
Neutral
high confidence
Mentioned
$ANIP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

The newest fact is the CFO’s planned open-market sale of 2,850 shares at $84.12, with holdings after the transaction of 177,543 shares.

02

Market read

Insider selling can influence short-term sentiment, but the 10b5-1 designation makes this more of a routine flow than a new fundamental signal.

03

What to watch

The filing does not disclose any new operational, financial, or regulatory information—so traders should avoid over-weighting it versus upcoming company catalysts (earnings, guidance, trial updates).

Relevance 3/10Novelty 3/10Timing: Filed after-hours on 2026-06-30 for a sale dated 2026-06-29

Background

The article is an SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, Inc. (ANIP).

Company-level read

Ticker impact

$ANIPNeutralHigh confidence
Context

ANIP’s SVP & CFO Stephen P. Carey filed a Form 4 selling 2,850 shares at $84.12 on 2026-06-29 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be small and fade as it’s a planned sale.

Evidence & confidence

The filing specifies code S (open-market sale) and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No sector read-across; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    ANI Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Stephen P. Carey

    SVP & CFO who sold shares (open-market sale) under a 10b5-1 plan.

  • trading plan
    10b5-1 plan

    Pre-arranged plan that typically reduces interpretive signal from insider selling.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIP insider trading history →

Related articles

OCT 12
$ANIPHighAI 8/10

ANI Pharmaceuticals Report Two-Year Vision Improvements In Phase 4 Eye Disease Study

ANI Pharmaceuticals (ANIP) reported positive results from its Phase 4 SYNCHRONICITY trial for the Fluocinolone Acetonide Intravitreal Implant in treating chronic non-infectious uveitis affecting the posterior segment of the eye. The trial met primary endpoints at six months and maintained improvements through 24 months. The implant is approved in the U.S. for chronic NIU-PS and diabetic macular edema. ANIP's stock closed at $73.89, up 2.65%.

rttnews.com2 min
OCT 12
$ANIPMedAI 8/10

ANI reports positive results from uveitis implant trial

ANI Pharmaceuticals (NASDAQ:ANIP) reported positive Phase 4 trial results for its fluocinolone acetonide implant in treating chronic non-infectious uveitis. The trial met primary endpoints, showing sustained improvements in visual acuity and central subfield thickness over 24 months. Adverse events included ocular hypertension and cataract. The implant was previously FDA-approved for diabetic macular edema and uveitis treatment.

investing.com2 min
OCT 12
$ANIPMedAI 8/10

After one implant, 79.6% of treated eyes had no inflammation return for two years

ANI Pharmaceuticals reported 6-month and 24-month data from its SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis. The trial met co-primary endpoints with statistical significance, showing improvements in visual acuity and central subfield thickness. At 24 months, 79.6% of treated eyes had no inflammation recurrence. Adverse events were consistent with prior trials.

stocktitan.net2 min
SEP 30
$ANIPMedAI 8/10

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

ANI Pharmaceuticals (ANIP) will present data from its Phase 4 SYNCHRONICITY trial and post-hoc analyses from the NEW DAY trial at the American Academy of Ophthalmology 2026 Meeting. The trials involve Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis and diabetic macular edema. The company also plans an encore presentation at the Hawaiian Eye & Retina 2027 Meeting.

globenewswire.com1 min